Loading
NASDAQHealthcareBiotechnology
Latest quote
$62.01
+$0.89 · +1.46%
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Previous close
$62.01
+$0.89 · +1.46%
Pre-market
$63.2553
+$1.2453 · +2.01%
Oct 9, 8:56 AM ET
Regular session · ET · Market data may be delayed.
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Day range
Current $62.01
52-week range
Current $62.01
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
47
Fair Value
Sentiment
71
Bullish
Risk
25
Moderate Risk
Momentum
66
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Day range
Current $62.01
52-week range
Current $62.01
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 88.04M USD | 18.47M USD | 7.53M USD | 94.59M USD | 70.43M USD |
| Cost of goods sold | 10.13M USD | 339.41M USD | 330.12M USD | 240.81M USD | 159.94M USD |
| Gross profit | 77.91M USD | −320.93M USD | −322.59M USD | −146.23M USD | −89.51M USD |
| Research and development | 405.9M USD | 339.41M USD | 330.12M USD | 240.81M USD | 159.94M USD |
| Selling, general, and administrative | 284.27M USD | 215.31M USD | 173.61M USD | 177.98M USD | 96.8M USD |
| Operating expenses | 690.17M USD | 215.31M USD | 173.61M USD | 177.98M USD | 96.8M USD |
| Interest income | 48.42M USD | 51.53M USD | 27.63M USD | 11.34M USD | 331K USD |
| Interest expense | 103.87M USD | 86.51M USD | 57.67M USD | 51.16M USD | 29.33M USD |
| Depreciation and amortization | 10.13M USD | 9.53M USD | 11.89M USD | 5.81M USD | 2.28M USD |
| Operating income | −612.26M USD | −536.25M USD | −496.21M USD | −324.2M USD | −186.31M USD |
| Net income | −784.96M USD | −589.53M USD | −526.24M USD | −388.96M USD | −215.31M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$112.6
81.58% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jun 25, 2013 | 1:6 | — | — |
Effective Jun 25, 2013
1:6
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI306.61M0.01%2.3T USD0.03%$379.56-0.39%
Vanguard Morningstar Small-Cap ETFVB221.56M0.12%185.3B USD0.03%$287.63+0.23%
iShares Russell 2000 ETFIWM216.45M0.28%77.7B USD0.19%$277.57-0.05%
Vanguard Morningstar Small-Cap Growth ETFVBK127.16M0.28%44.7B USD0.05%$340.59-0.48%
State Street SPDR S&P Biotech ETFXBI125.26M1.24%10.11B USD0.35%$149.29-0.63%
Vanguard Extended Market ETFVXF111.9M0.11%95.4B USD0.05%$233.13-0.15%
T. Rowe Capital Appreciation Equity ETFTCAF80.04M0.88%9.01B USD0.31%$43.20-0.58%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY64.35M0.25%25.53B USD0.23%$666.26+0.35%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap Growth ETFVBKState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFT. Rowe Capital Appreciation Equity ETFTCAFState Street SPDR S&P MIDCAP 400 ETF TrustMDYAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
